论文部分内容阅读
目的探究使用奥洛他定滴眼液+双氯芬酸钠滴眼液为过敏性结膜炎患者进行治疗的临床价值。方法 80例过敏性结膜炎患者,按患者入院时间分为单项治疗组和联合治疗组,每组40例。单项治疗组行奥洛他定滴眼液治疗,联合治疗组行奥洛他定滴眼液+双氯芬酸钠滴眼液治疗,对比两组患者的治疗效果、不良反应、临床症状和生命体征评分。结果联合治疗组总有效率为95.00%,单项治疗组为75.00%,比较差异有统计学意义(P<0.05)。两组患者治疗前临床症状和生命体征评分比较,差异无统计学意义(P>0.05);治疗后,联合治疗组评分明显高于单项治疗组(P<0.05)。联合治疗组不良反应发生率为7.50%,单项治疗组为15.00%,比较差异无统计学意义(P>0.05)。结论为过敏性结膜炎患者行奥洛他定滴眼液+双氯芬酸钠滴眼液治疗效果显著,且安全性高,可广泛应用。
Objective To investigate the clinical value of olopatadine eye drops + diclofenac sodium eye drops for the treatment of patients with allergic conjunctivitis. Methods Eighty patients with allergic conjunctivitis were divided into a single treatment group and a combined treatment group according to the time of admission. Each group included 40 cases. The single treatment group olopatadine eye drops treatment, combined treatment group olopatadine eye drops + diclofenac sodium eye drops treatment, the two groups were compared the treatment effect, adverse reactions, clinical symptoms and vital signs score. Results The total effective rate was 95.00% in the combined treatment group and 75.00% in the single treatment group, with significant difference (P <0.05). There was no significant difference in clinical symptom scores and vital signs scores between the two groups before treatment (P> 0.05). After treatment, the score of combined treatment group was significantly higher than that of single treatment group (P <0.05). The incidence of adverse reactions in combined treatment group was 7.50% and that in single treatment group was 15.00%, with no significant difference (P> 0.05). Conclusion The results show that olopatadine eye drops + diclofenac sodium eye drops for patients with allergic conjunctivitis are effective and safe, and can be widely used.